HELIUS MEDICAL TECHNOLOGIES (HSDT)

US42328V8019 - Common Stock

0.96  +0.05 (+5.49%)

After market: 0.8701 -0.09 (-9.36%)

Fundamental Rating

3

Overall HSDT gets a fundamental rating of 3 out of 10. We evaluated HSDT against 187 industry peers in the Health Care Equipment & Supplies industry. While HSDT seems to be doing ok healthwise, there are quite some concerns on its profitability. HSDT is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

HSDT had negative earnings in the past year.
In the past 5 years HSDT always reported negative net income.
In the past 5 years HSDT always reported negative operating cash flow.

1.2 Ratios

HSDT's Return On Assets of -158.62% is on the low side compared to the rest of the industry. HSDT is outperformed by 89.30% of its industry peers.
HSDT has a Return On Equity of -233.19%. This is in the lower half of the industry: HSDT underperforms 79.14% of its industry peers.
Industry RankSector Rank
ROA -158.62%
ROE -233.19%
ROIC N/A
ROA(3y)-108.35%
ROA(5y)-127.05%
ROE(3y)-236.75%
ROE(5y)-248.57%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HSDT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

HSDT does not have a ROIC to compare to the WACC, probably because it is not profitable.
HSDT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, HSDT has more shares outstanding
There is no outstanding debt for HSDT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -47.67, we must say that HSDT is in the distress zone and has some risk of bankruptcy.
HSDT has a Altman-Z score of -47.67. This is amonst the worse of the industry: HSDT underperforms 92.51% of its industry peers.
HSDT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -47.67
ROIC/WACCN/A
WACC9.16%

2.3 Liquidity

A Current Ratio of 3.61 indicates that HSDT has no problem at all paying its short term obligations.
The Current ratio of HSDT (3.61) is better than 64.17% of its industry peers.
A Quick Ratio of 3.10 indicates that HSDT has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.10, HSDT is doing good in the industry, outperforming 65.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.61
Quick Ratio 3.1

More info and screens

5

3. Growth

3.1 Past

HSDT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.24%, which is quite impressive.
The Revenue for HSDT has decreased by -18.17% in the past year. This is quite bad
Measured over the past years, HSDT shows a small growth in Revenue. The Revenue has been growing by 6.05% on average per year.
EPS 1Y (TTM)71.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.97%
Revenue 1Y (TTM)-18.17%
Revenue growth 3Y-0.81%
Revenue growth 5Y6.05%
Sales Q2Q%-64.34%

3.2 Future

The Earnings Per Share is expected to grow by 22.52% on average over the next years. This is a very strong growth
HSDT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 142.98% yearly.
EPS Next Y60.22%
EPS Next 2Y35.04%
EPS Next 3Y22.52%
EPS Next 5YN/A
Revenue Next Year-38.12%
Revenue Next 2Y-17.88%
Revenue Next 3Y5.69%
Revenue Next 5Y142.98%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HSDT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HSDT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as HSDT's earnings are expected to grow with 22.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.04%
EPS Next 3Y22.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HSDT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HELIUS MEDICAL TECHNOLOGIES

NASDAQ:HSDT (12/23/2024, 8:10:52 PM)

After market: 0.8701 -0.09 (-9.36%)

0.96

+0.05 (+5.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-11 2024-11-11/amc
Earnings (Next)N/A N/A
Inst Owners6.74%
Inst Owner Change-55.73%
Ins Owners0.24%
Ins Owner Change0%
Market Cap3.58M
Analysts43.33
Price Target4.08 (325%)
Short Float %2.42%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.53%
Min EPS beat(2)-25.49%
Max EPS beat(2)8.44%
EPS beat(4)3
Avg EPS beat(4)16.68%
Min EPS beat(4)-25.49%
Max EPS beat(4)61.81%
EPS beat(8)6
Avg EPS beat(8)14.77%
EPS beat(12)9
Avg EPS beat(12)17.4%
EPS beat(16)10
Avg EPS beat(16)-20.84%
Revenue beat(2)1
Avg Revenue beat(2)-23.86%
Min Revenue beat(2)-66.67%
Max Revenue beat(2)18.95%
Revenue beat(4)2
Avg Revenue beat(4)-23.24%
Min Revenue beat(4)-66.67%
Max Revenue beat(4)18.95%
Revenue beat(8)4
Avg Revenue beat(8)-21.74%
Revenue beat(12)7
Avg Revenue beat(12)-4.4%
Revenue beat(16)8
Avg Revenue beat(16)-3.81%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.17%
EPS NY rev (1m)0.35%
EPS NY rev (3m)0.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-62.69%
Revenue NY rev (1m)-36.33%
Revenue NY rev (3m)-36.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.13
P/FCF N/A
P/OCF N/A
P/B 0.94
P/tB 0.94
EV/EBITDA N/A
EPS(TTM)-6.18
EYN/A
EPS(NY)-2.55
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.13
BVpS1.02
TBVpS1.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -158.62%
ROE -233.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-108.35%
ROA(5y)-127.05%
ROE(3y)-236.75%
ROE(5y)-248.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.61
Quick Ratio 3.1
Altman-Z -47.67
F-ScoreN/A
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)14.64%
Cap/Depr(5y)48.54%
Cap/Sales(3y)6.07%
Cap/Sales(5y)10.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.97%
EPS Next Y60.22%
EPS Next 2Y35.04%
EPS Next 3Y22.52%
EPS Next 5YN/A
Revenue 1Y (TTM)-18.17%
Revenue growth 3Y-0.81%
Revenue growth 5Y6.05%
Sales Q2Q%-64.34%
Revenue Next Year-38.12%
Revenue Next 2Y-17.88%
Revenue Next 3Y5.69%
Revenue Next 5Y142.98%
EBIT growth 1Y16.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.21%
OCF growth 3YN/A
OCF growth 5YN/A